User:Mr. Ibrahem/Eribulin
Clinical data | |
---|---|
Trade names | Halaven |
Other names | E7389, ER-086526, NSC-707389, eribulin mesilate (JAN JP), eribulin mesylate (USAN US) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611007 |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
Drug class | Microtubule inhibitor[2] |
Legal status | |
Legal status | |
Identifiers | |
| |
Chemical and physical data | |
Formula | C40H59NO11 |
Molar mass | 729.908 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Eribulin, sold under the brand name Halaven, is a medication used to treat breast cancer and liposarcoma.[3][7] It is used when other treatments have failed.[7] It is given by injection into a vein.[3]
Common side effects include tiredness, hair loss, peripheral nerve damage, abdominal pain, fever, low white blood cells, and low red blood cells.[3] Other side effects may include low potassium, low calcium, and QT prolongation.[3] Use in pregnancy may harm the baby.[3] It is a microtubule inhibitor.[2]
Eribulin was approved for medical use in the United States in 2010 and Europe in 2011.[2][7] In the United Kingdom 0.88 mg cost the NHS about £360 as of 2021.[8] This amount in the United States costs about 580 USD.[9]
References[edit]
- ^ "Eribulin (Halaven) Use During Pregnancy". Drugs.com. 22 October 2019. Archived from the original on 11 July 2020. Retrieved 9 July 2020.
- ^ a b c "EriBULin Monograph for Professionals". Drugs.com. Archived from the original on 28 January 2021. Retrieved 15 December 2021.
- ^ a b c d e f g h "Halaven- eribulin mesylate injection". DailyMed. 22 December 2017. Archived from the original on 9 July 2020. Retrieved 9 July 2020.
- ^ "Eribulin EPAR". European Medicines Agency (EMA). Archived from the original on 9 July 2020. Retrieved 9 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Eisai Announces Japan Launch Of Anticancer Agent Halaven" (Press release). Eisai Co., Ltd. 19 July 2011. Archived from the original on 4 June 2021. Retrieved 15 February 2021.
- ^ "Anticancer Agent Halaven Approved For Treatment Of Locally Advanced Or Metastatic Breast Cancer In China" (Press release). Eisai Co., Ltd. 17 July 2019. Archived from the original on 4 June 2021. Retrieved 15 February 2021.
- ^ a b c "Halaven". Archived from the original on 9 July 2020. Retrieved 16 December 2021.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 977. ISBN 978-0857114105.
- ^ "Halaven Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 11 April 2021. Retrieved 16 December 2021.